Story

Guggenheim Names EyePoint Pharmaceuticals Top Biotech Pick with $68 Price Target

ENTHMSVIIDZHZH-TWJAKOHI
Aug 6, 20262 min read
Guggenheim Names EyePoint Pharmaceuticals Top Biotech Pick with $68 Price Target
Text size
Background

Guggenheim has identified EyePoint Pharmaceuticals (NASDAQ:EYPT) as its top pick in the biotech sector, initiating coverage with a $68 price target. The firm's positive outlook is based on the significant commercial potential of EyePoint's late-stage clinical program for Duravyu, a treatment for retinal disorders.

Key Clinical Catalysts Ahead

Guggenheim's analysis highlights a series of near-term events that could drive the stock's value. According to an update from EyePoint, the company is on schedule to release key clinical data in the coming months:

  • Topline data from its Phase III LUGANO study is expected in August 2026.
  • Data from the companion LUCIA study is now guided for the fourth quarter of 2026.
  • The first scientific disclosure of the LUGANO data to the medical community is planned for the Retina Society meeting in September.

Following the LUCIA data readout, EyePoint is positioned to file a New Drug Application (NDA) with regulators. Guggenheim stated it expects the LUGANO trial to meet its non-inferiority primary endpoint and demonstrate a meaningful reduction in patient treatment burden.

Valuation and Performance Metrics

Sample IUX Markets – In-articleAd

The firm's $68 price target is derived from a sum-of-the-parts, net-present-value (NPV) analysis. This valuation model includes the probability-adjusted future earnings of Duravyu and EyePoint's projected cash position at the end of 2025.

Guggenheim noted that investor focus has shifted to the drug's ability to reduce the frequency of treatments. The firm believes a "supplement-free rate" of approximately 50% would be sufficient to support a strong commercial launch, particularly if 60% to 70% of patients require zero or only one rescue treatment over the study period.

Broader Analyst Sentiment

The bullish call from Guggenheim follows other recent positive analyst coverage. Stifel recently initiated coverage on EyePoint with a buy rating, while Mizuho raised its price target on the stock to $39.

Adding to the positive momentum, EyePoint recently announced that an independent safety committee had completed a favorable review of its Phase 3 trials for DURAVYU, recommending the studies continue without modification.

Read next

More on Stocks
Back to latest news

LATEST